Core Viewpoint - The case highlights the issue of commercial bribery in the pharmaceutical industry, specifically involving a sales representative from Shandong Weigao Group Medical Polymer Co., Ltd., who engaged in bribery to influence prescription practices and disrupt fair competition in the healthcare sector [5][7]. Group 1: Bribery Details - The sales representative, Ci Mou Long, was found guilty of bribing staff at the Pu'er People's Hospital with a total of RMB 1,195,243 in cash and goods, including cash payments of RMB 395,000 and USD 9,900, as well as a gold bar weighing 200 grams [5][8]. - Between 2012 and 2020, Ci Mou Long made multiple payments to various hospital staff, including a total of RMB 290,000 in cash and a gold bar to the hospital's chief accountant, Liu Mou Wen, for facilitating payment settlements [8]. - The bribery involved various medical supplies, with cash kickbacks totaling RMB 408,200 and 500 supermarket vouchers distributed among nursing staff across different departments [13]. Group 2: Legal Consequences - Ci Mou Long was sentenced to 2 years and 6 months in prison and fined RMB 200,000 for his actions [7]. - The National Healthcare Security Administration (NHSA) plans to guide local healthcare authorities in conducting credit evaluations and enforcing measures against untrustworthy companies to protect healthcare fund security [7]. Group 3: Industry Implications - The NHSA has been actively reporting multiple cases of commercial bribery in the pharmaceutical sector to warn against unethical practices that undermine the integrity of medical services and increase healthcare costs [6].
金条、送美元、送现金 威高股份一业务员被国家医保局通报行贿